Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777708
Status:
TERMINATED
Last Update Posted:
2023-03-24
First Post:
2021-02-25
Brief Title:
BO-112 and Pembrolizumab for the Treatment of PD-1PD-L1 Refractory Liver Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Refractory Hepatocellular Carcinoma |
| Advanced Hepatocellular Carcinoma |
| BCLC Stage B Hepatocellular Carcinoma |
| BCLC Stage C Hepatocellular Carcinoma |
Keywords: